Pelubiprofen
| Code | Size | Price |
|---|
| TAR-T16464-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway. It also has significant anti-inflammatory and analgesic effects. Pelubiprofen is an orally active and non-steroidal anti-inflammatory drug and is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity .
CAS:
69956-77-0
Formula:
C16H18O3
Molecular Weight:
258.317
Pathway:
Neuroscience; Immunology/Inflammation
Purity:
0.98
SMILES:
CC(C(O)=O)c1ccc(C=C2/CCCCC2=O)cc1
Target:
COX
References
1. Choi IA, Baek HJ, et al. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC Musculoskelet Disord. 2014 Nov 18;15:375.